

1 **Identification of actionable genetic variants in 4,198 Scottish volunteers from the Viking Genes research**
2 **cohort and implementation of return of results**

3

4 Shona M. Kerr,^{1*} Lucija Klaric,^{1*} Marisa D. Muckian,^{2,3} Kiera Johnston,² Camilla Drake,¹ Mihail Halachev,¹
5 Emma Cowan,^{4,5} Lesley Snadden,^{4,5} John Dean,⁵ Sean L. Zheng,^{6,7,8} Prisca K. Thami,^{6,7} James S. Ware,^{6,7,8}
6 Gannie Tzoneva,⁹ Alan R. Shuldiner,⁹ Zosia Miedzybrodzka^{4,5} and James F. Wilson^{†1,2,10}

7

8 ¹MRC Human Genetics Unit, University of Edinburgh, Institute of Genetics and Cancer, Western General
9 Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.

10 ²Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh EH8
11 9AG, UK.

12 ³Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, Keppel
13 Street, London WC1E 7HT, UK.

14 ⁴Department of Medical Genetics, Ashgrove House, NHS Grampian, Aberdeen, AB25 2ZA, UK.

15 ⁵Medical Genetics Group, University of Aberdeen, Polwarth Building, Aberdeen, AB25 2ZD, UK.

16 ⁶National Heart and Lung Institute, Imperial College London, London, UK.

17 ⁷MRC Laboratory of Medical Sciences, Imperial College London, London, UK.

18 ⁸Royal Brompton & Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK.

19 ⁹Regeneron Genetics Center, Tarrytown, NY, USA.

20 ¹⁰Centre for Genomic and Experimental Medicine, University of Edinburgh, Institute of Genetics and
21 Cancer, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.

22

23 * These authors contributed equally

24 † Correspondence: jim.wilson@ed.ac.uk

25 **Abstract**

26 The benefits of returning clinically actionable genetic results to participants in research cohorts are
27 accruing, yet such a genome-first approach is challenging. Here, we describe the return of such results in
28 two founder populations from Scotland. Between 2005 and 2015, we recruited >4,000 adults with
29 grandparents from Orkney and Shetland into the Viking Genes research cohort. Return of genetic data
30 was not offered at baseline, but in 2023 we sent invitations for consent to return of actionable genetic
31 findings to participants. We generated exome sequence data from 4,198 participants, and used the ACMG
32 v3.2 list of 81 genes, ClinVar review and pathogenicity status, plus manual curation, to develop a pipeline
33 to identify potentially actionable variants. We identified 104 individuals (2.5%) carrying 108 actionable
34 genotypes at 39 variants in 23 genes, and validated these. Working with the NHS clinical genetics service,
35 which provided genetic counselling and clinical verification of the research results, and after expert clinical
36 review, we notified 64 consenting participants (or their next of kin) of their actionable genotypes. Ten
37 actionable variants across seven genes (*BRCA1*, *BRCA2*, *ATP7B*, *TTN*, *KCNH2*, *MUTYH*, *GAA*) have risen 50
38 to >3,000-fold in frequency through genetic drift in ancestral island localities. Viking Genes is one of the
39 first UK research cohorts to return actionable findings, providing an ethical and logistical exemplar of
40 return of results. The genetic structure in the Northern Isles of Scotland, with multiple founder effects,
41 provides a unique opportunity for a tailored approach to primary and secondary prevention through
42 genetic screening.

43

44 **Keywords**

45 Return of results, actionable variant, founder effect, exomes, Orkney, Shetland

46 Introduction

47 Where exome or genome sequencing is clinically indicated, the opportunity arises to report additional
48 incidental findings with the aim of diagnosis and pre-emptive clinical intervention. The American College
49 of Medical Genetics and Genomics (ACMG) has led this approach and annually updates a benchmark list of
50 genes for report¹. The list currently has 81 genes, which meet strict criteria: there must be strong evidence
51 that certain variants within the gene cause disease, and there must be effective medical intervention (for
52 example screening or medication) which can be offered to the carrier. The great majority of the genes are
53 associated with either inherited cancer predisposition, cardiovascular risk or metabolic diseases. These
54 conditions are mostly inherited in an autosomal dominant fashion, but variants in genes causing
55 autosomal recessive disease which are only actionable if homozygous or compound heterozygous are also
56 present in the ACMG v3.2 list. Although there has not yet been universal international adoption of this
57 approach, the ACMG list is the most widely used.

58 The consent obtained from participants in many research cohorts to date, including UK Biobank (UKB)²,
59 does not allow the return of results about actionable variants (AVs) or genotypes. However, some newer
60 US cohorts, such as *All of Us*, are committed to making their research results, including hereditary disease
61 risk, accessible to participants³. Geisinger's MyCode Community Health Initiative provides a model for
62 "genome-first" care⁴, and an international policy on return of results acknowledges the potential medical
63 benefits to the individuals who are participating in genomics research⁵.

64 The populations of the Northern Isles of Scotland – the Orkney and Shetland archipelagos - are the most
65 genetically isolated of all British and Irish populations, with the highest degree Norse admixture, and an
66 enrichment of rare and low frequency functional variants⁶⁻⁹. Viking Genes (viking.ed.ac.uk) comprises a set
67 of Northern and Western Isles population cohort studies, aiming to explore genetic causes of disease – the
68 Orkney Complex Disease Study (ORCADES), and VIKING I, II and III. ORCADES⁹ and VIKING I¹⁰ together
69 contain a rich data resource of more than 4,000 deeply phenotyped and exome sequenced research
70 subjects, nearly all with three or four grandparents from Orkney, or Shetland, respectively. In total, Viking
71 Genes has over 10,000 participants, all of whom consented to analysis of their DNA, and to be contacted
72 at a later date in connection with future ethically approved studies. We have previously reported founder

73 variants in *KCNH2*, *BRCA1* and *BRCA2* in Shetland and Orkney populations¹⁰⁻¹², with variants tracing back
74 to individual island ancestries.

75 In Viking Genes, all cohort members were offered the option of consent to return of actionable genetic
76 results. Building on a method developed by Kelly *et al*¹³ to screen 130,048 adults in the Geisinger MyCode
77 project, we used the ACMG v3.2 list¹ and variant classification information from the public database
78 ClinVar¹⁴ to code automated filters to identify potential actionable variants within 4,198 members of the
79 Viking Genes cohort. Here, we describe the analysis pipeline, summarize actionable results, the process of
80 returning these, and some challenges associated with implementation of these procedures at scale. We
81 provide evidence of multiple drifted actionable founder variants that could form the basis for a future
82 targeted Northern Isles population genetic screening programme.

83

84 **Subjects and Methods**

85 *Research Volunteer Recruitment and DNA Collection*

86 Recruitment to ORCADES took place from 2005-2011¹¹, and to Viking I (Viking Health Study – Shetland)
87 from 2013-2015¹⁰. Blood or occasionally saliva samples from participants were collected, processed and
88 stored using standard operating procedures and managed through a laboratory information management
89 system at the Edinburgh Clinical Research Facility, University of Edinburgh. Recruitment to VIKING II and
90 VIKING III took place online from January 2020 to March 2023¹⁵.

91 *Viking Genes Pedigree Information*

92 Records of the births, marriages and deaths in Orkney and Shetland are held at the General Register Office
93 for Scotland (New Register House, Edinburgh). These records, along with relationship information
94 obtained from study participants, Orkney and Shetland family history societies, and genealogies available
95 online, were used to construct pedigrees of study participants using RootsMagic software (S&N Genealogy
96 Supplies), which was then amended to reflect the genetic kinship between individuals using genotype
97 data.

98 *Genotyping*

99 DNA from all participants was used for genome-wide genotyping on the GSA BeadChip (Illumina) at the
100 Regeneron Genetics Center. Monomorphic genotypes and genotypes with more than 2% of missingness
101 and Hardy-Weinberg equilibrium (HWE) $p < 10^{-6}$ were removed, as well as individuals with more than 3% of
102 missingness.

103 *Exome Sequencing*

104 Quality controlled exome sequence data sets were prepared at the Regeneron Genetics Center, following
105 the process detailed for UKB², with 94.6% of targeted bases having >20X coverage.

106 *Pipeline Development*

107 To find carriers of actionable variants, we first extracted all variants that map to genes in the ACMG v3.2
108 list from the whole exome sequences (WES)¹. These variants were annotated with the dbsnp version 151
109 using the bcftools 1.9 annotate function, using CHROM, POS, ID, REF, ALT columns. The dbsnp 151 data was
110 downloaded from https://ftp.ncbi.nlm.nih.gov/snp/organisms/human_9606_b151_GRCh38p7/VCF/ (00-
111 All.vcf.gz file) in March 2022. To assess their pathogenicity, these variants were then merged with the
112 ClinVar data. The variant_summary.txt.gz file of the Clinvar data was downloaded on 18th March 2024,
113 from https://ftp.ncbi.nlm.nih.gov/pub/clinvar/tab_delimited/. Merging by chromosome, position
114 (genome build GRCh38), reference (REF) and alternate (ALT) alleles was necessary, since rsids can be
115 multiallelic - containing multiple variants at the same genomic position, including different nucleotide
116 substitutions, for example tri-allelic SNPs (A>C, A>G) as well as indels, and therefore merging solely by
117 rsids might result in merging different variants.

118 Some of the variants present in the exomes were not identical to mutations listed in ClinVar, but result in
119 the same amino-acid change as variants in ClinVar and thus the same consequence, commonly a
120 frameshift with comparable functional effects. Therefore, we also merged the variants from the WES with
121 ClinVar data based on the change of the amino-acid that the variant causes, instead of the CHR, POS, REF,
122 ALT. Furthermore, if the following hypothetical indel occurred, TCATCTA > TCATCTCTA, it could be
123 named either as c.4insCT or c.5insTC or c.6insCT, causing problems for merging the data using either of
124 the two approaches. This is illustrated by the real variant rs886044536, *TTN* c.93396_93400del AGCTT

125 ([MIM: 188840], Results). This is a deletion: GCCAAGCTAAGACT > GCCAAGACT which can be rendered
126 either as GCCAAG [CTAAG/*] ACT or as GCC [AAGCT/*] AAGACT.

127 After merging, we next filtered the output using the ClinVar annotations to retain only pathogenic or likely
128 pathogenic variants (P/LP), that had status 1 star or higher, that is with assertion of pathogenicity.

129 Moreover, the variant class had to match the disease-causing variant classes for that gene, e.g. only loss-
130 of-function (truncating) variants for titin (*TTN*). Variants were also subject to manual review before listing
131 as potentially actionable.

132 *Whole Genome Sequencing*

133 Whole genome sequencing (WGS) data is available for 1,300 members of the ORCADES cohort¹⁶ and 500
134 members of the Viking I cohort¹⁷. These datasets were used for look-ups, as part of the verification
135 process of the actionable variant results obtained from exome sequencing.

136 *Sanger Sequencing*

137 Pre-designed primer pairs for PCR and Sanger sequencing were selected from a collection that covers over
138 95% of human coding exons (Primer Designer, ThermoFisher Scientific). If validated primers were not
139 available, primer pairs were designed using Primer3 software (ThermoFisher Scientific) and checked using
140 UCSC In Silico PCR¹⁸. A standard protocol for PCR and Sanger sequencing on an Applied Biosystems 3730xl
141 Genetic Analyser was applied across all samples. Output files were analysed using Sequencher DNA
142 sequence analysis software version 5.4.6 (Gene Codes Corporation).

143 Validation of heterozygous short insertions/deletions (indels) can be challenging with Sanger sequencing.
144 Although still considered the gold standard, the sequencing ladders derived from, for example, the
145 deleted and non-deleted alleles become out of synchronicity with one another (by the length of the indel
146 in base-pairs), leading to double sequence after the indel in each direction. Illumina short read
147 sequencing, as used to generate the exome data, does not suffer from this problem. A further issue is that
148 certain indels with short repeats within or near them (or in low complexity DNA) can be rendered in
149 multiple ways in cDNA nomenclature, e.g. *TTN* c.93396_93400delAGCTT (see above). More common are
150 single base indels altering the length of homopolymers, which can be annotated as a change at any
151 position in, for example, the polyA tract. Chromosome positions are affected in the same way, and so

152 when interrogating ClinVar, we performed a secondary merge using the protein sequence nomenclature,
153 to pick up such instances.

154 *Clinical review of potentially actionable genotypes*

155 All potentially actionable variants and genotypes presented in Table S1 other than those noted as not
156 determined were discussed with the NHS clinical team in order to agree suitability for return of results to
157 participants. Local clinical knowledge in NHS Grampian was used as part of this review process.

158 *Electronic Health Record (EHR) Data Linkage*

159 This work used data provided by patients and collected by the NHS as part of their care and support,
160 reused with permission from Public Health Scotland. NHS routine datasets linked to ORCADES and VIKING
161 I participants in July 2021, including SMR01, the general/acute hospital inpatient and day case dataset of
162 episode level data, and SMR00, outpatient appointments and attendances, were accessed using a secure
163 process, as described previously¹¹.

164

165 **Results**

166 *Exome sequencing and validation*

167 Exome sequences were generated from 4,198 participants from the Viking Genes cohort using industry-
168 standard protocols as described in the Methods section. The exome sequence calls are of high quality, but
169 it is important to verify them in the research laboratory, before considering the process of notifying a
170 potential carrier. We therefore attempted to validate 149 potential actionable variant genotypes: 77 by
171 Sanger sequencing, 48 by WGS and 24 by both sequence analysis methods. The total of 149 includes a
172 number of heterozygous carriers of recessive variants in genes on the ACMGv3.2 list. 147 out of the 149
173 assessed were validated (98.7%). Notably, both of the variants that failed (one by Sanger sequencing
174 alone, and one by both Sanger sequencing and WGS) were only 2 kb apart in the same gene, *MSH2* [MIM:
175 609309]. Manual review of the exome read stacks suggests that these variants are both false positives,
176 with low read numbers and increased noise: they were not included in the total counts of actionable
177 variants found.

178 One variant, in *DES* [MIM: 125660], c.973C>T, was found to be most likely a somatic mosaic in the sample
179 of venous blood and so was not included in our counts and not returned. In Sanger sequencing from
180 forward and reverse strands, only a very weak T was observed, and the read counts in WGS were 19 C and
181 1T. In 85X exome data, the total read counts (sum of forward and reverse) are 72C, 13T, for a variant allele
182 distribution of 15%.

183 *Pipeline for identification of potential actionable variants*

184 Exome sequence data from 2,090 ORCADES participants (820 male and 1,270 female) and 2,108 VIKING I
185 participants (843 male and 1,265 female) passed all sequence and genotype quality control thresholds
186 (Methods). The data were run through our pipeline (Methods), a key component of which is the ClinVar
187 resource (www.ncbi.nlm.nih.gov/clinvar/). ClinVar aggregates information about genomic variation and its
188 relationship to human health and allocates a clinical significance category to each variant¹⁴.

189 In total, 59 potential actionable variants were observed, consisting of 27 singletons (Supplemental Table
190 S1) and 32 non-singleton variants (Tables 1 and 2). Half of the singleton variants (13/27) were observed in
191 participants with one non-islander parent, and a further 4/27 were in volunteers with one non-islander
192 grandparent, for a total of 63% of singletons with at least one quarter non-Northern Isles DNA. The
193 remaining 10 singletons presumably arose by mutation in the last few generations and are thus very rare,
194 or were brought into the islands by non-parental events. The variants were found in 26 different genes.
195 For three of these genes, *BTD* [MIM: 609019], *CASQ2* [MIM: 114251] and *RPE65* [MIM: 180069], each
196 carrier only had a single copy of a variant that acts recessively, thus not an actionable genotype. In this
197 paper we are careful to distinguish between actionable variants (from the ACMG list) and actionable
198 genotypes, the combinations of such variants which are actionable, for example compound heterozygotes
199 or homozygotes for autosomal recessive conditions. Altogether, using the 81-gene ACMG 3.2 list, we
200 observed actionable genotypes for 104 individuals (2.5% of the population) carrying 108 actionable
201 genotypes at 39 of the variants, across 23 genes. No X-linked actionable variants were found.

202 The level of support for each review status in ClinVar decreases from four star downwards
203 (https://www.ncbi.nlm.nih.gov/clinvar/docs/review_status). The great majority of the actionable variants

204 we found were 3 (reviewed by expert panel) or 2 (criteria provided, multiple submitters, no conflicts) star
205 (Table S1). Three of the non-singleton autosomal dominant actionable variants (Table 1) had a review
206 status in ClinVar of 1 star, all of which had a single submitter. The paucity of submissions often indicates
207 rarity of the variant, which in turn makes assessment of pathogenicity and hence actionability more
208 challenging.

209 *Actionable genotype co-occurrences*

210 We identified four individuals with actionable genotypes in two separate genes (Table 3). We expect some
211 such co-occurrences because of independent assortment, and we should see these according to the
212 product of the allele frequencies of the variants in question. If one or both have drifted upwards in
213 frequency, more will be seen. We found that two of these four Viking Genes individuals had AVs in two
214 different cancer susceptibility genes, while two had actionable genotypes in a cancer susceptibility gene
215 and a metabolic gene.

216 *Drifted actionable variants in Northern Isles populations*

217 The isolated Northern Isles populations carry different sets of rare variants compared to cosmopolitan
218 populations. In total, 10 actionable variants across 7 genes (*BRCA1* [MIM: 113705], *BRCA2* [MIM:600185],
219 *ATP7B* [MIM: 606882], *TTN* [MIM: 188840], *KCNH2* [MIM: 152427], *MUTYH* [MIM: 604933], *GAA* [MIM:
220 606800]) have risen in frequency by at least 50-fold through the action of genetic drift in the Northern
221 Isles (Table 4). These include results published previously on a *BRCA1* breast and ovarian cancer
222 predisposition variant that is 470-fold more common in Orkney than in the UK¹¹, a *KCNH2* Long QT
223 Syndrome variant that is ~90-fold more common in Shetland¹⁰, and a pathogenic *BRCA2* variant ~155-fold
224 more common in Shetland¹².

225 Most actionable variants in the ACMG list have a dominant mode of inheritance and so are actionable if
226 heterozygous, but some are only considered actionable if present in two copies. Table 4 includes five
227 drifted variants in Northern Isles populations that act recessively (also listed in Table 2). These are in
228 *ATP7B* (three drifted variants segregating in our cohorts), *MUTYH* and *GAA*. Wilson Disease [MIM:
229 277900] is a disorder of copper metabolism, caused by variants in the copper transporting ATPase gene
230 *ATP7B*. The marked discrepancy between the “genetic prevalence” in populations and the number of

231 clinically diagnosed cases of Wilson Disease is probably due both to reduced penetrance of many *ATP7B*
232 mutations, and failure to diagnose patients with this highly treatable disorder¹⁹. We identified three
233 founder effects on recessive *ATP7B* Wilson disease variants, two in Shetland, which gives rise to
234 substantial risk of homozygosity or compound heterozygosity. The combined allele frequency in
235 Shetlanders is 0.8%. Together with five other alleles segregating at lower frequencies, the sum
236 Pathogenic/Likely Pathogenic (P/LP) allele frequency is 1.12%; thus about 1/45 Shetlanders are carriers of
237 P/LP *ATP7B* variants. Under random mating, this predicts about 1/8000 will be homozygotes or compound
238 heterozygotes, at risk of being affected. Indeed, one homozygote for the drifted variant c.3007G>A was
239 found.

240 There is a founder effect on a recessive *MUTYH* variant (c.1130C>T) in Orkney (0.86% carriers, 70x more
241 common than UKB), causing *MYH*-associated polyposis [MIM: 608456] (Table 4). While not increased in
242 frequency compared to other populations, there are two further *MUTYH* variants segregating in the
243 Orcadian population, bringing the combined carrier frequency to 2.9%. This suggests that 1/35 Orcadians
244 are carriers and, assuming random mating among Orcadians, an expectation that ~1/5000 will be at risk of
245 *MYH*-associated polyposis. Consistent with this, we did observe a compound heterozygote in the Orkney
246 data.

247 Finally, there are also founder effects in Shetland on two dominant loss-of-function titin (*TTN*) variants,
248 increasing the risk of dilated cardiomyopathy [MIM: 604145] (Table 4). One of these, c.93396_93400del, is
249 >3,000-fold more common in Shetland than in UKB, where there is only a single instance in 917,682
250 alleles. Together with a third returnable *TTN* variant that does not meet our thresholds to be defined as
251 drifted, the combined allele frequency is 0.5%, meaning 1/100 Shetlanders are carriers. In total, we
252 observed 24 carriers of *TTN* loss-of-function (LoF) variants (23 of which are accounted for by these three
253 alleles).

254 *An ultra-rare drifted titin variant*

255 The penetrance of the *TTN* alleles included in ClinVar as pathogenic or likely pathogenic is variable and age
256 related. However, the deletion of 5 nucleotides c.93396_93400del causes a frameshift, which creates a
257 premature translational stop signal (p.Trp31134*), predicted to result in an absent or disrupted protein

258 product. This variant is in the A-band of the *TTN* gene. Truncating variants in the A-band of *TTN* are
259 significantly overrepresented in patients with dilated cardiomyopathy (DCM), and are considered to be
260 likely pathogenic for the disease²⁰. *TTN* truncating variants (TTNtv) located in exons highly expressed in
261 the heart (proportion spliced in [PSI]>0.9, or hiPSI), such as this one, increase the odds of DCM by 11-19-
262 fold²¹. This variant has therefore been classified as Likely Pathogenic in ClinVar. We examined data from
263 347 individuals ascertained with DCM and found to carry hiPSI TTNtv in DCM cohort studies from Europe,
264 USA and Australia, and also interrogated data from TTNtv carriers in the UKB²², the Geisinger MyCode
265 Biobank and the PennMedicine Biobank (168 affected with DCM, 2,409 unaffected)²¹. In total we observed
266 1,200 distinct hiPSI TTNtv in 2,094 individuals. The c.93396_93400del variant was observed twice (1 in
267 UKB and 1 in MyCode), both times in individuals without a diagnosis of DCM. The variant was not
268 observed in the 100,000 Genomes Project²³ (670 DCM cases, 62,330 non-DCM participants) or All of Us²⁴
269 (245,460 total participants, of whom 125,860 were reported as European heritage), and therefore can be
270 considered ultra-rare.

271 Analysis of linked data from the EHR for cardiomyopathy (ICD-10 code I42), atrial fibrillation (ICD-10 I48)
272 or heart failure (ICD-10 I50) shows that the 16 carriers of the drifted *TTN* variant c.93396_93400del we
273 identified in VIKING I are nearly four times more likely ($P=0.02$, Fisher's exact test) to have an inpatient or
274 day patient record for cardiomyopathy (1/16), atrial fibrillation (2/16) or heart failure (2/16) than non-
275 carriers (4/16 carriers have entries for at least one of these conditions, i.e. a nominal combined
276 penetrance of 25%, versus a prevalence of 6.8% in 4,133 individuals without *TTN* LoF variants). Analysis of
277 ECG data collected in the VIKING 1 recruitment clinic from 15 of the carriers also shows an over-
278 representation of features such as first degree atrioventricular block (3/15) or right bundle branch block
279 (4/15), affecting a total of 7 carriers. In one Shetland *TTN* c.93396_93400del family investigated clinically,
280 the condition has typically been detectable on echocardiography around age 30, but symptoms have not
281 developed until later. One patient required a cardiac resynchronisation therapy-defibrillator, while
282 another is asymptomatic despite an abnormal echocardiogram in their late 50s. Together with the 7
283 entries in ClinVar submitted to date, we now report this further direct evidence for pathogenicity of this
284 ultra-rare drifted *TTN* variant.

285 *Impact of sub-population gene pools*

286 The drifted variants are not shared between the two archipelagos, except *TTN* p.Gln22507Ter, which is
287 observed in Shetland among individuals with recent Orcadian ancestry; and *MUTYH* p.Pro377Leu, for
288 which the Shetland carriers have no recent Orcadian ancestry. This latter variant may have been
289 introduced to the Northern Isles more than once, or there may be unrecorded non-parental events
290 connecting the Orcadian and Shetlandic kindreds.

291 The great majority of these actionable variants can be traced back to individual isles within Orkney or
292 Shetland, or in some cases individual parishes: 13-15 ancient geographic, legal, and religious subdivisions
293 of the Mainlands of Orkney and Shetland (Figure 1). Among published variants, 95% of carriers of the
294 drifted *BRCA1* variant traced their genealogies to Westray, in the North Isles of Orkney¹¹, while 78% of the
295 drifted *BRCA2* variant carriers trace back to Whalsay, an isle in Shetland¹². Likewise, drifted *KCNH2* variant
296 carriers from Viking Genes and NHS Clinical Genetics¹⁰ trace back either to the parish of Aithsting in the
297 West Mainland of Shetland or Unst in the North Isles of Shetland (Figure 1 and Table 4).

298 Among the drifted variants reported here, 80% of the carriers of the most drifted *ATP7B* variant have
299 genealogies going back to Burra Isle, Shetland and there is also a strong founder effect on the most highly
300 drifted *TTN* variant c.93396_93400del, this time in Yell, in the North Isles of Shetland, with 100% of
301 carriers tracing their family trees back to there. Further fine scale, within-archipelago population
302 structuring of clinically important variants is observed in Westray, in the North Isles of Orkney, with
303 another *ATP7B* variant having drifted to high frequencies there, and 100% of carriers tracing pedigrees
304 there, similarly to a *MUTYH* variant, where 60% of carriers have Westray genealogies; indeed, we
305 observed a compound heterozygote with ancestry from that isle.

306 *Genetic down-drift*

307 It is more difficult to quantify which variants have drifted down in frequency, but the near absence of
308 familial hypercholesterolaemia (FH) [MIM: 143890 and MIM:144010] variants is notable, with only one
309 carrier across >4,000 subjects. This *LDLR* [MIM: 606945] variant was observed in Shetland and is the
310 known p.C163Y West of Scotland founder variant²⁵; it may have been brought to the isles by recent gene
311 flow from Mainland Scotland; no FH variants were observed in Orkney. No P/LP *APOB* [MIM:107730] or

312 *PCSK9* [MIM: 607786] variants were observed. Significantly fewer volunteers from the Northern Isles
313 carried FH variants than observed in European ancestry participants from the UKB ($P < 0.0001$, Fisher's
314 exact test). The carrier frequency in the Northern Isles (1/4198) is more than 10-fold lower than that in
315 UKB European ancestry subjects (1/288)²⁶.

316 *The Return of Results (RoR) process*

317 With reference to the Association of Clinical Genomic Science (ACGS) guidelines
318 (<https://www.acgs.uk.com/media/12533/uk-practice-guidelines-for-variant-classification-v12-2024.pdf>)
319 and local clinical knowledge, four variants in a total of 10 genotype carriers were not deemed returnable
320 by the NHS clinical team (Table 5 and Table S1). Our next goal was to implement a process of return of
321 results (RoR) to carrier participants, summarised in Figure 2. Key principles include: the use of informed
322 consent; respecting the right not to know; checking the research results as far as possible before sharing a
323 potentially actionable variant ID; decisions on whether to return a variant result taken by NHS clinical
324 experts; counselling provided through the NHS, and verification of all the research results in an accredited
325 clinical laboratory. The consent form and RoR participant information sheets sent to cohort members are
326 provided as supplemental information. Frequently asked questions about return of results are available
327 for participants on the study website at [https://viking.ed.ac.uk/for-viking-genes-volunteers/faqs/return-](https://viking.ed.ac.uk/for-viking-genes-volunteers/faqs/return-of-results)
328 [of-results](https://viking.ed.ac.uk/for-viking-genes-volunteers/faqs/return-of-results)

329 We obtained a favourable opinion from the Research Ethics Committee to return results of genotypes that
330 have the potential to improve the health of the individuals carrying them. We subsequently obtained
331 further permission to contact male carriers of pathogenic *BRCA1* variants. This was justified by the fact
332 that although there is no clinical action to be taken with respect to the letter recipient, the information
333 could be of value to their female relatives, who may not be Viking Genes research participants. There are
334 13 male carriers of the *BRCA1* p.V1736A variant in the ORCADES cohort¹¹ and none in VIKING I, so addition
335 of these participants increases the total number of actionable genotypes from 108 to 121. Since there are
336 four individuals with two actionable genotypes each (Table 3), this corresponds to a total of 117 total
337 actionable genotype carriers (Table 5).

338 We further obtained ethical permission to offer actionable results to the next of kin of deceased
339 participants, if we found any that might have been relevant to the health of the participant who died, and
340 therefore potentially their family, during our research (Figure 2). To date, six next of kin have provided
341 their consent to receive this information, with one actionable genotype disclosed.

342 The process we have implemented is in good accordance with a checklist of components for return of
343 results developed by an interdisciplinary panel of European experts²⁷. In Viking Genes, the return of
344 medically actionable genetic results to participants is optional, i.e. an opt-in approach. This has legal,
345 philosophical, and ethical foundations, to allow patient autonomy and the right not to know. This is
346 achieved at three separate points in the process of implementation (Figure 2). Letters containing results
347 are only sent with the consent of the recipient. Upon receipt, the participant can decline any further
348 investigation by not contacting the NHS about the research finding. Finally, after genetic counselling, the
349 patient can decide not to have the research result confirmed in a clinical setting. It should also be noted
350 that a participant can get in touch with Viking Genes at any time to request to change the consent they
351 gave about RoR, in either direction, or to withdraw from the study. The research team communicates with
352 Viking Genes volunteers by regular newsletters and social media, and invites them to complete occasional
353 research surveys. A subset of participants in the study forms the public - participant involvement (PPI)
354 group. We therefore aim to ensure both that understanding of the opportunity to receive results is high,
355 and the processes we are implementing have the support of the study participants and the populations
356 they are drawn from.

357 *Initial outcomes from issuing RoR letters*

358 The text of the letters alerting the volunteer to the research result is written in lay language, agreed by
359 the research and NHS teams, and the template document was given a favourable opinion by the Research
360 Ethics Committee. The NHS clinic team is not made aware of the identity of the research participants, but
361 approves return of the variants, which are also noted in the letters. Letters were not sent to all carrier
362 participants at one time. Instead, the 64 RoR letters issued (Table 5) were posted over the course of
363 almost exactly one year. This was designed to prevent the NHS clinics from being overwhelmed, but has
364 meant that outcomes are still being accumulated. For example, it is too early to tally the number of family

365 members contacted by cascade testing from each index case. In the NHS, each index case on average
366 leads to three subsequent cascade tests, half of which are positive²⁸. In the case of the Shetland *BRCA2*
367 founder variant c.517-2A>G, a total of 56 people were eligible for cascade letters from just 5 consented
368 carriers in Viking Genes, suggesting a higher level of knowledge of family structure among our
369 participants. We observe that RoR letter recipients take a variable length of time to decide whether to
370 contact the NHS, and not all choose to do so.

371 In all three of the previously reported actionable founder variants¹⁰⁻¹², we identified carriers in our
372 research populations who could not have been ascertained from oral history-based cascade testing.
373 Likewise, many of the index cases described here were found to be in family groups not previously
374 recorded by the clinical geneticists. Out-patient NHS EHR data showed that only 9% of our carriers had
375 interacted with clinical genetics, compared with 3.6% of the non-carriers, a 2.5-fold increase ($P < 0.002$, χ^2).
376 This provides further evidence that a substantial number of the research participants who received a
377 return of results letter were previously unaware of the genomic medicine finding, and have the
378 opportunity for preventative medical intervention as a result of the Viking Genes return of results
379 programme.

380

381 **Discussion**

382 *Survey of Actionable Variants*

383 We observed actionable genotypes for 39 autosomal actionable variants, 34 dominant and 5 recessive,
384 and no X-linked variants. Ten founder variants showed strong enrichment, having risen >50-fold in
385 frequency in Orkney or Shetland, while otherwise commonly seen variants, notably those causing familial
386 hypercholesterolaemia, were at least ten-fold lower in frequency. Importantly, both *TTN* and *ATP7B*
387 contain multiple drifted variants, which sum together to even higher frequencies of (likely) pathogenic
388 variation.

389 The ten actionable variants which have drifted up to much higher frequencies in Orkney or Shetland than
390 in the general UK population mostly have a clear origin in a particular parish or isle within the Northern
391 Isles, 200 or more years ago, highlighting the continuing clinical importance of these historic sub-

392 population gene pools. As is the case with other genetic isolate populations²⁹, the combination of multiple
393 founder variants can result in a significant summed population frequency, sometimes in conjunction with
394 non-drifted variants. At the same time, other variants have drifted towards loss, balancing the genetic
395 burden of disease risk.

396 *Comparisons with other populations surveyed for actionable variants*

397 Overall, these two UK isolate populations have a similar percentage of actionable genotypes (2.5%),
398 compared to cosmopolitan populations worldwide. However, the number carrying one or more actionable
399 genotypes depends on the gene list, rules applied (including bespoke curation) and date of analysis. The
400 ACMG list of recommendations of genes and phenotypes is updated annually, whereas ClinVar is designed
401 to enable the ongoing evolution and development of knowledge regarding variations and associated
402 phenotypes, and its website is updated weekly. The status of a variant, particularly if observed rarely
403 worldwide, may therefore change over time as more data are submitted, interpreted and reported in
404 ClinVar. This makes it challenging to compare our Viking Genes actionable variant carrier percentage with
405 populations reported in other publications. In the first 50,000 exome sequences from the UKB population
406 cohort, an actionable genotype figure of 2.0% was reported². However, that analysis used v2.0 of the
407 ACMG list³⁰, containing 59 genes, rather than the 81 in v3.2 that were surveyed here. Similarly, a figure of
408 2.8% can be calculated from the DiscovEHR study³¹ and 2.3% in Iceland³², using the ACMG list v2.0.
409 Another way to compare with studies in other populations is to use the ACMG 2.0 (59 gene) list to assess
410 our data in the Northern Isles population, in which case the percentage with actionable genotypes drops
411 to 1.4%.

412 The inclusion of *HFE* [MIM: 613609] p.Cys282Tyr homozygotes, in later versions of the list, would on its
413 own increase the percentage of actionable genotype carriers in the UKB from 2.0% to 2.6%. This is based
414 on the *HFE* variant having a reported homozygous frequency of 0.6%, or 1 in 156, in the UKB³³. We
415 therefore show here that the Northern Isles populations have an AV percentage that is in a similar range
416 to the rest of the population of the UK as sampled in the UKB, to the DiscovEHR study of people in
417 Pennsylvania, USA, and to the Icelandic population (4.0% in the most recent analysis, including manual
418 curation)³², but much lower than that reported for the Old Order Amish of Pennsylvania³⁴.

419 We identified a sufficient number of carriers to provide specific evidence for pathogenicity of one drifted
420 variant in *TTN*, c.93396_93400del, p.Trp31134*. A total of 44 genes were recently asserted to be
421 implicated in non-syndromic Dilated Cardiomyopathy (DCM) by the ClinGen DCM Gene Curation Expert
422 Panel³⁵. *TTN* is one of 11 genes with definite evidence, and featured in a gene-based analysis of
423 penetrance and clinical phenotype in 18,665 UKB participants³⁶. A sub-analysis for genes including *TTN*
424 revealed DCM or early DCM features in 45.4% of cases³⁶. Moreover, significant excess mortality was
425 observed among carriers of *TTN* truncating variants in Dutch founder pedigrees, driven by subjects ≥ 60
426 years³⁷.

427 *Return of Results to Research Volunteers - Benefits and Challenges*

428 The return of results processes that we successfully implemented for Viking Genes participants as
429 described here were somewhat more straightforward than they would be in cosmopolitan populations,
430 due to the reduced number of different actionable variants in the ancestral populations of the Northern
431 Isles of Scotland, and the high support for and trust in scientific research in these communities.
432 Nonetheless, the processes and experiences of returning actionable genetic results in Viking Genes are
433 directly relevant as an exemplar (especially in the UK) for other research cohorts interested in the
434 feasibility and logistics of the return of actionable results to their participants. Our recent recruitment to a
435 new cohort study, VIKING II, was eligible to people of Northern Isles ancestry regardless of domicile¹⁵. At
436 the outset of recruitment, VIKING II offered the option of consent to return of selected clinically
437 actionable results. This option was chosen by an overwhelming majority (98%), 6,054 of the 6,178
438 participants who consented and completed the study questionnaire. This is in good agreement with
439 several other studies that also show strong support for receiving actionable findings, both in theory and in
440 practice^{38,39}. These views may mean that the return of actionable genetic findings from research will in
441 future become the default practice³⁹. However, the costs, harms and benefits of returning actionable
442 results are still at an early stage of being fully characterized.

443 For some diseases in the ACMG list, there can often be a long delay before accurate diagnosis, due to the
444 overlap of symptoms with other more prevalent conditions. Examples we have found in Viking Genes
445 include Pompe disease [MIM: 232300], caused by a deficiency of the enzyme acid alpha-glucosidase

446 (GAA), which can lead to nerve and muscle problems, Wilson disease [MIM: 277900], caused by copper
447 overload, and the iron overload condition hereditary haemochromatosis [MIM: 235200] (*HFE*). Early
448 diagnosis and thus early intervention can have an impact on future quality of life. Furthermore, in addition
449 to the medical intervention available for each actionable result, a clearer diagnosis/etiology following the
450 return of results can also be of value, for those already affected, particularly for conditions like
451 cardiomyopathy which have complex symptoms and presentation. Increased awareness of these
452 otherwise rare conditions among healthcare workers in the Northern Isles could lead to decreased times
453 to diagnosis, with concomitant benefits to patients.

454 Cross-sectional approaches, for example to understand the penetrance of rare-variants in
455 cardiomyopathy-associated genes, can provide valuable data⁴⁰, and genome-first evaluation at scale can
456 enable new diagnoses missing from clinical healthcare⁴¹. However, the scientific literature is only just
457 beginning to provide insight into how the ACMG guidelines have been translated into precision health
458 outcomes for the recipients of the findings: for some genes benefits clearly outweigh harms, while for
459 others there is little evidence as yet⁴²⁻⁴⁴. This is likely to gather pace in the near future, as more large scale
460 initiatives such as All of Us³, the Healthy Oregon Project⁴⁵ and the Colorado Center for Personalized
461 Medicine⁴⁶ implement the return of actionable results. Furthermore, disease manifestation, healthcare
462 outcomes and costs of disclosure have recently been described for actionable findings in a UK setting from
463 the Genomics England 100,000 Genomes Project⁴⁷. Genomics England returned results for actionable
464 genotypes in 13 genes within the 81 genes on the ACMG3.2 list, for hereditary cancer syndromes and
465 familial hypercholesterolaemia, plus carrier status for cystic fibrosis ([MIM: 219700], not on the ACMG
466 list). Due to a lack of consensus on benefit versus harm and the challenges of reduced penetrance,
467 Genomics England chose not to inform carriers of actionable genotypes increasing the risk of Long QT
468 syndrome, cardiomyopathies, aortopathies, further inherited cancers, metabolic diseases and the most
469 frequent genetic disease, hereditary haemochromatosis ([www.genomicsengland.co.uk/initiatives/100000-](http://www.genomicsengland.co.uk/initiatives/100000-genomes-project/additional-findings)
470 [genomes-project/additional-findings](http://www.genomicsengland.co.uk/initiatives/100000-genomes-project/additional-findings)).

471 Jensson *et al*³² found shorter median survival among persons carrying actionable genotypes than among
472 non-carriers, in Iceland. Specifically, they report that carrying an actionable genotype in a cancer gene on

473 the ACMG list was associated with life span that was three years shorter than that among noncarriers,
474 with causes of death among carriers attributed primarily to cancer-related conditions. Furthermore, while
475 many studies have demonstrated the diagnostic and therapeutic value of exome or whole genome
476 sequencing in critically ill paediatric cases, a recent study shows that the diagnostic utility of exome
477 sequencing in critically ill adults is similar, largely due to uncovering variants in medically actionable
478 genes⁴⁸.

479 Our data highlight the clinical relevance of local genetic sub-populations, as most of the founder variants
480 are also associated with one or other parish or isle, with deep genealogies linking most carriers to
481 ancestors from there (notwithstanding ancestral non-parental events which obscure the connection
482 between genetics and geography). Within each archipelago, it is natural that historic barriers to marriage
483 in the form of storm-prone, strongly tidal ocean and sea channels and sounds, have given rise to
484 subpopulation gene pools or micro-isolates^{7,49}. Within the main islands, the parishes are sometimes
485 separated by low hills or sea firths, and sometimes not, but marriage records show they were
486 demographically important over the centuries.

487 *Population Screening Opportunities*

488 Population screening in a clinical context is currently available in some populations that show founder
489 effects, such as an NHS programme offering *BRCA*-testing to those with Jewish ancestry
490 (<https://www.nhsjewishbrcaprogramme.org.uk/>). Charitable organisations are also increasingly making
491 specific genetic tests available to populations of higher risk. Examples include improving the prevention
492 and diagnosis of Jewish genetic disorders in the UK (<https://www.jnetics.org/>) and the provision of postal
493 tests for genetic haemochromatosis (<https://www.haemochromatosis.org.uk/>).

494 Our estimates of the frequency of the *BRCA1* and *BRCA2* actionable variants in Westray and Whalsay,
495 respectively, (1/19 and 1/43)¹² show that the local gene pool frequencies can be much higher than the
496 archipelago-wide frequencies. This in turn suggests that individuals with ancestry from islands such as Yell,
497 Burra and Westray are at higher risk of being carriers than the Shetland- or Orkney-wide data suggest. The
498 ability to target testing to those with an origin in a particular parish may improve the cost-effectiveness of
499 future screening. At the same time, with increasing movement, younger generations and inhabitants of

500 the towns of Kirkwall and Lerwick (and of course the diasporas outside the Northern Isles) tend to have
501 more mixed ancestry, so the importance of these micro-isolates is waning.

502 We report four actionable genotype co-occurrences. Many more instances in other populations are likely
503 to be uncovered in the future, as genetic analyses move from limited gene panels towards WES and WGS.

504 A recent review, for example, describes Multi-locus Inherited Neoplasia Allele Syndrome (MINAS), which
505 refers to individuals with germline pathogenic variants in two or more cancer susceptibility genes⁵⁰.

506 We have not investigated LoF variants that may be present in our data, but which are not reported in
507 ClinVar. There may be potentially important ultra-rare variants in this class, which warrants future
508 research. Furthermore, clinically relevant variants that lie outside of exomes, and structural variants, may
509 be uncovered in subsequent research. However, except for the most drifted variants, the assessment of
510 pathogenicity will always be limited by the modest numbers of carriers likely to be found in our cohorts.

511 We also note that the high levels of engagement and knowledge of kinship led to higher uptake of cascade
512 testing, and thus a higher-than-expected demand on clinical services, compared to previous cascade
513 testing statistics reported in the NHS²⁸.

514 Studies of population genetic structure using unselected genome-wide markers^{7,51} are not always
515 considered relevant for clinical genetics. However, a number of reports now demonstrate the
516 consequences of such population structure for clinical genetics at the population level. A case in point is
517 the Irish Travellers, shown to be a distinct population isolate of Irish origin⁵² with their own suite of
518 Mendelian conditions at high frequencies⁵³. Similarly, the genetic isolation of Orkney and Shetland has
519 been shown to translate into clinically important differences at the population level, from the earliest
520 studies of Northern Isles genetics, showing a founder effect on the *SOD1* [MIM: 147450] p.D90A allele⁵⁴,
521 to novel Mendelian conditions⁵⁵⁻⁵⁷, and distinct blood group/isozyme⁵⁸ and uniparental⁶ markers. More
522 recently, numerous founder effects, both on Mendelian recessive alleles⁸, and on dominant actionable
523 variants¹⁰⁻¹² have been described.

524 Orcadians and Shetlanders thus belong to a group of European-heritage populations, including Ashkenazi
525 Jews and Irish Travellers, where high frequencies of important clinical variants have arisen from genetic

526 drift, with concomitant simplification of the gene pools providing valuable opportunities for population-
527 wide, cost-effective targeted genetic screening.

528

529 **Data and Code Availability Statement**

530 There is neither Research Ethics Committee approval, nor consent from Viking Genes participants, to
531 permit open release of the individual level research data underlying this study. The datasets generated
532 and analysed during the current study are therefore not publicly available. Instead, the research data
533 and/or DNA samples are available from accessQTL@ed.ac.uk on reasonable request, following approval by
534 the Data Access Committee and in line with the consent given by participants. The ClinVar-exome pipeline
535 code is available on GitHub (https://github.com/viking-genes/clinvar_pipeline). Frequencies for the ten
536 drifted variants reported here were derived from the UK Biobank Whole Genome Sequencing (WGS)
537 project and were obtained from the publicly available UK Biobank Allele Frequency Browser
538 (<https://afb.ukbiobank.ac.uk/>), which was generated by the WGS consortium under the UK Biobank
539 Resource (project ID 52293).

540 **Acknowledgments**

541 This work was funded by the Medical Research Council University Unit award to the MRC Human Genetics
542 Unit, University of Edinburgh, MC_UU_00007/10 and a Wellcome Trust Institutional Translational
543 Partnership Award (University of Edinburgh 222060/Z/20/Z -PIII031). LK was supported by an RCUK
544 Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1). ORCADES was
545 supported by the Chief Scientist Office of the Scottish Government (CZB/4/276 and CZB/4/710), a Royal
546 Society URF to JFW, and Arthritis Research UK. JSW was supported by the Medical Research Council (UK),
547 Sir Jules Thorn Charitable Trust (21JTA), British Heart Foundation (RE/18/4/34215), and the NIHR Imperial
548 College Biomedical Research Centre. This research has been conducted using the UK Biobank Resource
549 under Application Numbers 47602 and 19655.
550 Emily Weiss and Reka Nagy assembled the Orkney pedigree, and Barbara Gray the Shetland pedigree,
551 using records at the General Register Office, the Shetland Family History Society, and study information,
552 building on earlier pedigree work by Ruth McQuillan and Jim Wilson. Sanger sequencing was performed

553 by the technical services team at the MRC Human Genetics Unit. We thank the NHS Grampian clinical
554 genetics team and the Viking Genes research team (in particular David Buchanan, Rachel Edwards and
555 Craig Sinclair) for their contributions to the implementation of the return of results process. Finally, we
556 thank the people of the Northern and Western Isles for their involvement in and ongoing support for our
557 research.

558 **Author Contributions**

559 SMK managed the project and drafted the manuscript. LK created and implemented the ClinVar-exome
560 pipeline, with input and support from KJ, and analysed the exome datasets. MDM updated the pipeline.
561 CD validated exome data by PCR and Sanger sequencing of genomic DNA. MH validated exome data by
562 analysis of WGS data. SMK, ZM and JFW planned the RoR methodology. ZM and JD provided information
563 on the clinical epidemiology of the Northern Isles and clinically reviewed the variants to be reported. JSW,
564 SLZ and PKT interpreted phenotype data in cardiomyopathy variant carriers. GT and ARS conceived and
565 managed the Viking Genes exome sequencing. ZM led the NHS RoR clinical team, which included genetic
566 counsellors EC and LS, who discussed actionable results with participants. JFW is the Chief Investigator of
567 Viking Genes, was awarded funding to implement the work, analysed the data and helped draft the
568 manuscript. All authors provided input and feedback on drafts of the manuscript.

569 **Ethical Approval**

570 Eligible participants were recruited to Viking Genes, NHS Lothian South East Scotland Research Ethics
571 Committee reference 19/SS/0104. Research participants gave informed consent for research procedures
572 including DNA sequencing (mandatory) and return of actionable results (optional).

573

574 For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to
575 any Author Accepted Manuscript version arising from this submission.

576

577 **Supplemental Files**

578 Supplemental Table S1 All actionable variants reported by our ClinVar pipeline.

579 Supplemental Information – RoR Participant Information Sheet (PIS), RoR Consent Form and RoR PIS for
580 Next of Kin.

581

582 Declaration of Interests

583 AS and GT are employees and/or stockholders of Regeneron Genetics Center or Regeneron
584 Pharmaceuticals. LK is an employee of BioAge Labs and holds share options. JSW has received research
585 support from Bristol Myers Squibb, and has acted as a consultant for MyoKardia, Pfizer, Foresite Labs,
586 Health Lumen, and Tenaya Therapeutics.

587

588 References


- 589 1. Miller, D.T., Lee, K., Abul-Husn, N.S., Amendola, L.M., Brothers, K., Chung, W.K., Gollob, M.H.,
590 Gordon, A.S., Harrison, S.M., Hershberger, R.E., et al. (2023). ACMG SF v3.2 list for reporting of
591 secondary findings in clinical exome and genome sequencing: A policy statement of the American
592 College of Medical Genetics and Genomics (ACMG). *Genet Med* 25, 100866.
593 [10.1016/j.gim.2023.100866](https://doi.org/10.1016/j.gim.2023.100866).
- 594 2. Van Hout, C.V., Tachmazidou, I., Backman, J.D., Hoffman, J.D., Liu, D., Pandey, A.K., Gonzaga-
595 Jauregui, C., Khalid, S., Ye, B., Banerjee, N., et al. (2020). Exome sequencing and characterization
596 of 49,960 individuals in the UK Biobank. *Nature* 586, 749-756. [10.1038/s41586-020-2853-0](https://doi.org/10.1038/s41586-020-2853-0).
- 597 3. Venner, E., Muzny, D., Smith, J.D., Walker, K., Neben, C.L., Lockwood, C.M., Empey, P.E., Metcalf,
598 G.A., Kachulis, C., All of Us Research Program Regulatory Working, G., et al. (2022). Whole-
599 genome sequencing as an investigational device for return of hereditary disease risk and
600 pharmacogenomic results as part of the All of Us Research Program. *Genome Med* 14, 34.
601 [10.1186/s13073-022-01031-z](https://doi.org/10.1186/s13073-022-01031-z).
- 602 4. Schwartz, M.L.B., McCormick, C.Z., Lazzeri, A.L., Lindbuchler, D.M., Hallquist, M.L.G., Manickam,
603 K., Buchanan, A.H., Rahm, A.K., Giovanni, M.A., Frisbie, L., et al. (2018). A Model for Genome-First
604 Care: Returning Secondary Genomic Findings to Participants and Their Healthcare Providers in a
605 Large Research Cohort. *Am J Hum Genet* 103, 328-337. [10.1016/j.ajhg.2018.07.009](https://doi.org/10.1016/j.ajhg.2018.07.009).
- 606 5. Lewis, A.C.F., Knoppers, B.M., and Green, R.C. (2021). An international policy on returning
607 genomic research results. *Genome Med* 13, 115. [10.1186/s13073-021-00928-5](https://doi.org/10.1186/s13073-021-00928-5).
- 608 6. Wilson, J.F., Weiss, D.A., Richards, M., Thomas, M.G., Bradman, N., and Goldstein, D.B. (2001).
609 Genetic evidence for different male and female roles during cultural transitions in the British Isles.
610 *Proc Natl Acad Sci U S A* 98, 5078-5083. [10.1073/pnas.071036898](https://doi.org/10.1073/pnas.071036898).
- 611 7. Gilbert, E., O'Reilly, S., Merrigan, M., McGettigan, D., Vitart, V., Joshi, P.K., Clark, D.W., Campbell,
612 H., Hayward, C., Ring, S.M., et al. (2019). The genetic landscape of Scotland and the Isles. *Proc Natl*
613 *Acad Sci U S A* 116, 19064-19070. [10.1073/pnas.1904761116](https://doi.org/10.1073/pnas.1904761116).
- 614 8. Halachev, M., Gountouna, V.E., Meynert, A., Tzoneva, G., Shuldiner, A.R., Semple, C.A., and
615 Wilson, J.F. (2024). Regionally enriched rare deleterious exonic variants in the UK and Ireland. *Nat*
616 *Commun* 15, 8454. [10.1038/s41467-024-51604-2](https://doi.org/10.1038/s41467-024-51604-2).
- 617 9. McQuillan, R., Leutenegger, A.L., Abdel-Rahman, R., Franklin, C.S., Pericic, M., Barac-Lauc, L.,
618 Smolej-Narancic, N., Janicijevic, B., Polasek, O., Tenesa, A., et al. (2008). Runs of homozygosity in
619 European populations. *Am J Hum Genet* 83, 359-372. [10.1016/j.ajhg.2008.08.007](https://doi.org/10.1016/j.ajhg.2008.08.007).
- 620 10. Kerr, S.M., Klaric, L., Halachev, M., Hayward, C., Boutin, T.S., Meynert, A.M., Semple, C.A.,
621 Tuiskula, A.M., Swan, H., Santoyo-Lopez, J., et al. (2019). An actionable KCNH2 Long QT Syndrome

- 622 variant detected by sequence and haplotype analysis in a population research cohort. *Sci Rep* 9,
623 10964. [10.1038/s41598-019-47436-6](https://doi.org/10.1038/s41598-019-47436-6).
- 624 11. Kerr, S.M., Cowan, E., Klaric, L., Bell, C., O'Sullivan, D., Buchanan, D., Grzymalski, J.J., van Hout, C.V.,
625 Tzoneva, G., Shuldiner, A.R., et al. (2023). Clinical case study meets population cohort:
626 identification of a BRCA1 pathogenic founder variant in Orcadians. *Eur J Hum Genet* 31, 588-595.
627 [10.1038/s41431-023-01297-w](https://doi.org/10.1038/s41431-023-01297-w).
- 628 12. Kerr, S.M., Klaric, L., Muckian, M.D., Cowan, E., Snadden, L., Tzoneva, G., Shuldiner, A.R.,
629 Miedzybrodzka, Z., and Wilson, J.F. (2024). Two founder variants account for over 90% of
630 pathogenic BRCA alleles in the Orkney and Shetland Isles in Scotland. *European Journal of Human*
631 *Genetics*. [10.1038/s41431-024-01704-w](https://doi.org/10.1038/s41431-024-01704-w).
- 632 13. Kelly, M.A., Leader, J.B., Wain, K.E., Bodian, D., Oetjens, M.T., Ledbetter, D.H., Martin, C.L., and
633 Strande, N.T. (2021). Leveraging population-based exome screening to impact clinical care: The
634 evolution of variant assessment in the Geisinger MyCode research project. *Am J Med Genet C*
635 *Semin Med Genet* 187, 83-94. [10.1002/ajmg.c.31887](https://doi.org/10.1002/ajmg.c.31887).
- 636 14. Landrum, M.J., Chitipiralla, S., Brown, G.R., Chen, C., Gu, B., Hart, J., Hoffman, D., Jang, W., Kaur,
637 K., Liu, C., et al. (2020). ClinVar: improvements to accessing data. *Nucleic Acids Res* 48, D835-
638 D844. [10.1093/nar/gkz972](https://doi.org/10.1093/nar/gkz972).
- 639 15. Kerr, S., Edwards, R., Buchanan, D., Dean, J., Miedzybrodzka, Z., and Wilson, J. (2023). VIKING II, a
640 Worldwide Observational Cohort of Volunteers with Northern Isles Ancestry. *International Journal*
641 *of Population Data Science* 8. [10.23889/ijpds.v8i1.2121](https://doi.org/10.23889/ijpds.v8i1.2121).
- 642 16. Gilly, A., Klaric, L., Park, Y.C., Png, G., Barysenka, A., Marsh, J.A., Tsafantakis, E., Karaleftheri, M.,
643 Dedoussis, G., Wilson, J.F., and Zeggini, E. (2022). Gene-based whole genome sequencing meta-
644 analysis of 250 circulating proteins in three isolated European populations. *Mol Metab* 61,
645 101509. [10.1016/j.molmet.2022.101509](https://doi.org/10.1016/j.molmet.2022.101509).
- 646 17. Halachev, M., Meynert, A., Taylor, M.S., Vitart, V., Kerr, S.M., Klaric, L., Consortium, S.G.P., Aitman,
647 T.J., Haley, C.S., Prendergast, J.G., et al. (2019). Increased ultra-rare variant load in an isolated
648 Scottish population impacts exonic and regulatory regions. *PLoS Genet* 15, e1008480.
649 [10.1371/journal.pgen.1008480](https://doi.org/10.1371/journal.pgen.1008480).
- 650 18. Raney, B.J., Barber, G.P., Benet-Pages, A., Casper, J., Clawson, H., Cline, M.S., Diekhans, M.,
651 Fischer, C., Navarro Gonzalez, J., Hickey, G., et al. (2024). The UCSC Genome Browser database:
652 2024 update. *Nucleic Acids Res* 52, D1082-D1088. [10.1093/nar/gkad987](https://doi.org/10.1093/nar/gkad987).
- 653 19. Wallace, D.F., and Dooley, J.S. (2020). ATP7B variant penetrance explains differences between
654 genetic and clinical prevalence estimates for Wilson disease. *Hum Genet* 139, 1065-1075.
655 [10.1007/s00439-020-02161-3](https://doi.org/10.1007/s00439-020-02161-3).
- 656 20. Roberts, A.M., Ware, J.S., Herman, D.S., Schafer, S., Baksi, J., Bick, A.G., Buchan, R.J., Walsh, R.,
657 John, S., Wilkinson, S., et al. (2015). Integrated allelic, transcriptional, and phenomic dissection of
658 the cardiac effects of titin truncations in health and disease. *Sci Transl Med* 7, 270ra276.
659 [10.1126/scitranslmed.3010134](https://doi.org/10.1126/scitranslmed.3010134).
- 660 21. Haggerty, C.M., Damrauer, S.M., Levin, M.G., Birtwell, D., Carey, D.J., Golden, A.M., Hartzel, D.N.,
661 Hu, Y., Judy, R., Kelly, M.A., et al. (2019). Genomics-First Evaluation of Heart Disease Associated
662 With Titin-Truncating Variants. *Circulation* 140, 42-54. [10.1161/CIRCULATIONAHA.119.039573](https://doi.org/10.1161/CIRCULATIONAHA.119.039573).
- 663 22. Backman, J.D., Li, A.H., Marcketta, A., Sun, D., Mbatchou, J., Kessler, M.D., Benner, C., Liu, D.,
664 Locke, A.E., Balasubramanian, S., et al. (2021). Exome sequencing and analysis of 454,787 UK
665 Biobank participants. *Nature* 599, 628-634. [10.1038/s41586-021-04103-z](https://doi.org/10.1038/s41586-021-04103-z).
- 666 23. Investigators, G.P.P., Smedley, D., Smith, K.R., Martin, A., Thomas, E.A., McDonagh, E.M., Cipriani,
667 V., Ellingford, J.M., Arno, G., Tucci, A., et al. (2021). 100,000 Genomes Pilot on Rare-Disease
668 Diagnosis in Health Care - Preliminary Report. *N Engl J Med* 385, 1868-1880.
669 [10.1056/NEJMoa2035790](https://doi.org/10.1056/NEJMoa2035790).
- 670 24. Bick, A.G., Metcalf, G.A., Mayo, K.R., Lichtenstein, L., Rura, S., Carroll, R.J., Musick, A., Linder, J.E.,
671 Jordan, I.K., Nagar, S.D., et al. (2024). Genomic data in the All of Us Research Program. *Nature*
672 627, 340-346. [10.1038/s41586-023-06957-x](https://doi.org/10.1038/s41586-023-06957-x).
- 673 25. Lee, W.K., Haddad, L., Macleod, M.J., Dorrance, A.M., Wilson, D.J., Gaffney, D., Dominiczak, M.H.,
674 Packard, C.J., Day, I.N., Humphries, S.E., and Dominiczak, A.F. (1998). Identification of a common

- 675 low density lipoprotein receptor mutation (C163Y) in the west of Scotland. *J Med Genet* 35, 573-
676 578. [10.1136/jmg.35.7.573](https://doi.org/10.1136/jmg.35.7.573).
- 677 26. Gratton, J., Humphries, S.E., and Futema, M. (2023). Prevalence of FH-Causing Variants and Impact
678 on LDL-C Concentration in European, South Asian, and African Ancestry Groups of the UK Biobank-
679 Brief Report. *Arterioscler Thromb Vasc Biol* 43, 1737-1742. [10.1161/ATVBAHA.123.319438](https://doi.org/10.1161/ATVBAHA.123.319438).
- 680 27. Vears, D.F., Hallowell, N., Bentzen, H.B., Ellul, B., Nost, T.H., Kerasidou, A., Kerr, S.M., Th
681 Mayrhofer, M., Mezinska, S., Ormondroyd, E., et al. (2023). A practical checklist for return of
682 results from genomic research in the European context. *Eur J Hum Genet* 31, 687-695.
683 [10.1038/s41431-023-01328-6](https://doi.org/10.1038/s41431-023-01328-6).
- 684 28. Woodward, E.R., Green, K., Burghel, G.J., Bulman, M., Clancy, T., Lalloo, F., Schlecht, H., Wallace,
685 A.J., and Evans, D.G. (2022). 30 year experience of index case identification and outcomes of
686 cascade testing in high-risk breast and colorectal cancer predisposition genes. *Eur J Hum Genet*
687 30, 413-419. [10.1038/s41431-021-01011-8](https://doi.org/10.1038/s41431-021-01011-8).
- 688 29. Hamel, N., Kotar, K., and Foulkes, W.D. (2003). Founder mutations in BRCA1/2 are not frequent in
689 Canadian Ashkenazi Jewish men with prostate cancer. *BMC Med Genet* 4, 7. [10.1186/1471-2350-](https://doi.org/10.1186/1471-2350-4-7)
690 4-7.
- 691 30. Kalia, S.S., Adelman, K., Bale, S.J., Chung, W.K., Eng, C., Evans, J.P., Herman, G.E., Hufnagel, S.B.,
692 Klein, T.E., Korf, B.R., et al. (2017). Recommendations for reporting of secondary findings in clinical
693 exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American
694 College of Medical Genetics and Genomics. *Genet Med* 19, 249-255. [10.1038/gim.2016.190](https://doi.org/10.1038/gim.2016.190).
- 695 31. Dewey, F.E., Murray, M.F., Overton, J.D., Habegger, L., Leader, J.B., Fetterolf, S.N., O'Dushlaine, C.,
696 Van Hout, C.V., Staples, J., Gonzaga-Jauregui, C., et al. (2016). Distribution and clinical impact of
697 functional variants in 50,726 whole-exome sequences from the DiscovEHR study. *Science* 354.
698 [10.1126/science.aaf6814](https://doi.org/10.1126/science.aaf6814).
- 699 32. Jensson, B.O., Arnadottir, G.A., Katrinardottir, H., Fridriksdottir, R., Helgason, H., Oddsson, A.,
700 Sveinbjornsson, G., Eggertsson, H.P., Halldorsson, G.H., Atlason, B.A., et al. (2023). Actionable
701 Genotypes and Their Association with Life Span in Iceland. *N Engl J Med* 389, 1741-1752.
702 [10.1056/NEJMoa2300792](https://doi.org/10.1056/NEJMoa2300792).
- 703 33. Pilling, L.C., Tamosauskaite, J., Jones, G., Wood, A.R., Jones, L., Kuo, C.-L., Kuchel, G.A., Ferrucci, L.,
704 and Melzer, D. (2019). Common conditions associated with hereditary haemochromatosis genetic
705 variants: cohort study in UK Biobank. *BMJ* 364, k5222. [10.1136/bmj.k5222](https://doi.org/10.1136/bmj.k5222).
- 706 34. Lynch, M.T., Maloney, K.A., Pollin, T.I., Streeten, E.A., Xu, H., Regeneron Genetics, C., Shuldiner,
707 A.R., Van Hout, C.V., Gonzaga-Jauregui, C., and Mitchell, B.D. (2021). The burden of pathogenic
708 variants in clinically actionable genes in a founder population. *Am J Med Genet A* 185, 3476-3484.
709 [10.1002/ajmg.a.62472](https://doi.org/10.1002/ajmg.a.62472).
- 710 35. Jordan, E., Peterson, L., Ai, T., Asatryan, B., Bronicki, L., Brown, E., Celeghin, R., Edwards, M., Fan,
711 J., Ingles, J., et al. (2021). Evidence-Based Assessment of Genes in Dilated Cardiomyopathy.
712 *Circulation* 144, 7-19. [10.1161/CIRCULATIONAHA.120.053033](https://doi.org/10.1161/CIRCULATIONAHA.120.053033).
- 713 36. Shah, R.A., Asatryan, B., Sharaf Dabbagh, G., Aung, N., Khanji, M.Y., Lopes, L.R., van Duijvenboden,
714 S., Holmes, A., Muser, D., Landstrom, A.P., et al. (2022). Frequency, Penetrance, and Variable
715 Expressivity of Dilated Cardiomyopathy-Associated Putative Pathogenic Gene Variants in UK
716 Biobank Participants. *Circulation* 146, 110-124. [10.1161/CIRCULATIONAHA.121.058143](https://doi.org/10.1161/CIRCULATIONAHA.121.058143).
- 717 37. Jansen, M., Baas, A.F., van Spaendonck-Zwarts, K.Y., Ummels, A.S., van den Wijngaard, A.,
718 Jongbloed, J.D.H., van Slegtenhorst, M.A., Lekanne Deprez, R.H., Wessels, M.W., Michels, M., et al.
719 (2019). Mortality Risk Associated With Truncating Founder Mutations in Titin. *Circ Genom Precis*
720 *Med* 12, e002436. [10.1161/circgen.118.002436](https://doi.org/10.1161/circgen.118.002436).
- 721 38. Middleton, A., Morley, K.I., Bragin, E., Firth, H.V., Hurles, M.E., Wright, C.F., Parker, M., and study,
722 D.D.D. (2016). Attitudes of nearly 7000 health professionals, genomic researchers and publics
723 toward the return of incidental results from sequencing research. *Eur J Hum Genet* 24, 21-29.
724 [10.1038/ejhg.2015.58](https://doi.org/10.1038/ejhg.2015.58).
- 725 39. Schupmann, W., Miner, S.A., Sullivan, H.K., Glover, J.R., Hall, J.E., Schurman, S.H., and Berkman,
726 B.E. (2021). Exploring the motivations of research participants who chose not to learn medically

- 727 actionable secondary genetic findings about themselves. *Genet Med* 23, 2281-2288.
728 10.1038/s41436-021-01271-1.
- 729 40. McGurk, K.A., Zhang, X., Theotokis, P., Thomson, K., Harper, A., Buchan, R.J., Mazaika, E.,
730 Ormondroyd, E., Wright, W.T., Macaya, D., et al. (2023). The penetrance of rare variants in
731 cardiomyopathy-associated genes: A cross-sectional approach to estimating penetrance for
732 secondary findings. *Am J Hum Genet* 110, 1482-1495. 10.1016/j.ajhg.2023.08.003.
- 733 41. Forrest, I.S., Duffy, A., Park, J.K., Vy, H.M.T., Pasquale, L.R., Nadkarni, G.N., Cho, J.H., and Do, R.
734 (2024). Genome-first evaluation with exome sequence and clinical data uncovers underdiagnosed
735 genetic disorders in a large healthcare system. *Cell Rep Med*, 101518.
736 10.1016/j.xcrm.2024.101518.
- 737 42. Sapp, J.C., Facio, F.M., Cooper, D., Lewis, K.L., Modlin, E., van der Wees, P., and Biesecker, L.G.
738 (2021). A systematic literature review of disclosure practices and reported outcomes for medically
739 actionable genomic secondary findings. *Genet Med* 23, 2260-2269. 10.1038/s41436-021-01295-7.
- 740 43. Blout Zawatsky, C.L., Shah, N., Machini, K., Perez, E., Christensen, K.D., Zouk, H., Steeves, M., Koch,
741 C., Uveges, M., Shea, J., et al. (2021). Returning actionable genomic results in a research biobank:
742 Analytic validity, clinical implementation, and resource utilization. *Am J Hum Genet* 108, 2224-
743 2237. 10.1016/j.ajhg.2021.10.005.
- 744 44. Clayton, E.W., Smith, M.E., Anderson, K.C., Chung, W.K., Connolly, J.J., Fullerton, S.M., McGowan,
745 M.L., Peterson, J.F., Prows, C.A., Sabatello, M., and Holm, I.A. (2023). Studying the impact of
746 translational genomic research: Lessons from eMERGE. *Am J Hum Genet* 110, 1021-1033.
747 10.1016/j.ajhg.2023.05.011.
- 748 45. O'Brien, T.D., Potter, A.B., Driscoll, C.C., Goh, G., Letaw, J.H., McCabe, S., Thanner, J., Kulkarni, A.,
749 Wong, R., Medica, S., et al. (2023). Population screening shows risk of inherited cancer and
750 familial hypercholesterolemia in Oregon. *Am J Hum Genet* 110, 1249-1265.
751 10.1016/j.ajhg.2023.06.014.
- 752 46. Wiley, L.K., Shortt, J.A., Roberts, E.R., Lowery, J., Kudron, E., Lin, M., Mayer, D., Wilson, M.,
753 Brunetti, T.M., Chavan, S., et al. (2024). Building a vertically integrated genomic learning health
754 system: The biobank at the Colorado Center for Personalized Medicine. *Am J Hum Genet* 111, 11-
755 23. 10.1016/j.ajhg.2023.12.001.
- 756 47. Nolan, J., Buchanan, J., Taylor, J., Almeida, J., Bedenham, T., Blair, E., Broadgate, S., Butler, S.,
757 Cazeaux, A., Craft, J., et al. (2023). Secondary (additional) findings from the 100,000 Genomes
758 Project: disease manifestation, healthcare outcomes and costs of disclosure. *Genet Med*, 101051.
759 10.1016/j.gim.2023.101051.
- 760 48. Gold, J., Kripke, C.M., Center, R.G., BioBank, P.M., and Drivas, T.G. (2024). Universal Exome
761 Sequencing in Critically Ill Adults: A Diagnostic Yield of 25% and Race-Based Disparities in Access to
762 Genetic Testing. *medRxiv*, 2024.2003.2011.24304088. 10.1101/2024.03.11.24304088.
- 763 49. O'Dushlaine, C., McQuillan, R., Weale, M.E., Crouch, D.J., Johansson, A., Aulchenko, Y., Franklin,
764 C.S., Polasek, O., Fuchsberger, C., Corvin, A., et al. (2010). Genes predict village of origin in rural
765 Europe. *Eur J Hum Genet* 18, 1269-1270. 10.1038/ejhg.2010.92.
- 766 50. McGuigan, A., Whitworth, J., Andreou, A., Hearn, T., Genomics England Research, C., Tischkowitz,
767 M., and Maher, E.R. (2022). Multilocus Inherited Neoplasia Allele Syndrome (MINAS): an update.
768 *Eur J Hum Genet* 30, 265-270. 10.1038/s41431-021-01013-6.
- 769 51. Leslie, S., Winney, B., Hellenthal, G., Davison, D., Boumertit, A., Day, T., Hutnik, K., Royrvik, E.C.,
770 Cunliffe, B., Wellcome Trust Case Control, C., et al. (2015). The fine-scale genetic structure of the
771 British population. *Nature* 519, 309-314. 10.1038/nature14230.
- 772 52. Gilbert, E., Carmi, S., Ennis, S., Wilson, J.F., and Cavalleri, G.L. (2017). Genomic insights into the
773 population structure and history of the Irish Travellers. *Sci Rep* 7, 42187. 10.1038/srep42187.
- 774 53. Lynch, S.A., Crushell, E., Lambert, D.M., Byrne, N., Gorman, K., King, M.D., Green, A., O'Sullivan, S.,
775 Browne, F., Hughes, J., et al. (2018). Catalogue of inherited disorders found among the Irish
776 Traveller population. *J Med Genet* 55, 233-239. 10.1136/jmedgenet-2017-104974.
- 777 54. Welch, S.G., and Mears, G.W. (1972). Genetic variants of human indophenol oxidase in the
778 Westray Island of the Orkneys. *Hum Hered* 22, 38-41. 10.1159/000152465.
- 779 55. Rennie, A.G. (1983). The Whalsay cataract. *Trans Ophthalmol Soc U K* (1962) 103 (Pt 5), 530-531.

- 780 56. Muir, V.M. (1978). Tylosis in the Orkney islands. *J Biosoc Sci* *10*, 1-6.
781 10.1017/s0021932000011408.
- 782 57. Rugg, E.L., Common, J.E., Wilgoss, A., Stevens, H.P., Buchan, J., Leigh, I.M., and Kelsell, D.P. (2002).
783 Diagnosis and confirmation of epidermolytic palmoplantar keratoderma by the identification of
784 mutations in keratin 9 using denaturing high-performance liquid chromatography. *Br J Dermatol*
785 *146*, 952-957. 10.1046/j.1365-2133.2002.04764.x.
- 786 58. Roberts, D.F. (1986). Who are the Orcadians? *Anthropologischer Anzeiger* *44*, 93-104.
- 787
- 788



789

790 **Figure 1 Isles and parishes of Orkney and Shetland.** Each archipelago consists of a larger island called the

791 Mainland, with surrounding smaller isles. Both island groups can be divided into 4-6 larger areas, such as

792 West Shetland (known locally as the West side) or the West Mainland of Orkney, which in turn are

793 organised into 25 parishes or isles. Founder effects are usually concentrated in one parish/isle or in one of


794 the larger contiguous areas. W&W, Whiteness & Weisdale; Tin, Tingwall; Ler, Lerwick; St A, St. Andrews;

795 K&StO, Kirkwall & St. Ola; Orp, Orphir; Ste, Stenness; Str, Stromness; San, Sandwick (Orkney); Bir, Birsay;

796 Evi, Evie; Ren, Rendall; Fir, Firth; Har, Harray.

797

798



799

800 **Figure 2. Overview of Viking Genes return of results.** Processes implemented by the Viking Genes

801 research team are boxed with no shading; processes implemented by the NHS clinical team are shaded.

802 PIS, participant information sheet (see Supplemental information).

category	disease	gene	c.	p.	clin sig	actionable	consequence	LoF	star
cancer	breast-ovarian cancer, familial	<i>BRCA1</i>	c.5207T>C	p.Val1736Ala	pathogenic	All P and LP	missense	0	3
		<i>BRCA2</i>	c.517-2A>G	.	pathogenic	All P and LP	splice acceptor	1	3
	Lynch syndrome	<i>MSH6</i>	c.3261dup	p.Phe1088fs	pathogenic	All P and LP	frameshift	1	3
	attenuated familial adenomatous polyposis	<i>APC</i>	c.154C>T	p.Gln52Ter	pathogenic	All P and LP	stop gain	1	2
	multiple endocrine neoplasia	<i>RET</i>	c.2410G>A	p.Val804Met	P/LP	All P and LP	missense	0	2
metabolic	hereditary transthyretin amyloidosis	<i>TTR</i>	c.262A>T	p.Ile88Leu	P/LP	All P and LP	missense	0	2
cardiovascular	long QT syndrome	<i>KCNH2</i>	c.1750G>A	p.Gly584Ser	P/LP	All P and LP	missense	0	2
		<i>SCN5A</i>	c.4716C>T	p.Gly1572=	P/LP	All P and LP	splice donor	1	2
	dilated cardiomyopathy	<i>TTN</i>	c.1558dupA*	p.Thr520fs	LP	only LOF	frameshift	1	1
		<i>TTN</i>	c.67519C>T	p.Gln22507Ter	LP	only LOF	stop gain	1	1
		<i>TTN</i>	c.88837A>T	p.Lys29613Ter	P/LP	only LOF	stop gain	1	2
		<i>TTN</i>	c.93396_93400del	p.Ala31133_Trp31134insTer	P/LP	only LOF	frameshift	1	2
vascular Ehlers-Danlos syndrome	<i>COL3A1</i>	c.944G>C*	p.Gly315Ala	LP	All P and LP	missense	0	1	

Table 1 Summary of non-singleton autosomal dominant actionable variants in the cohort of 4,198 participants. The diseases are grouped into the categories of cancer, metabolic and cardiovascular. c., coding sequence change; p., protein sequence change; clin sig, clinical significance according to ClinVar; LP, likely pathogenic; P/LP, pathogenic/likely pathogenic; actionable, variant categories considered to be actionable; LOF, loss of function; consequence, the molecular consequence of the variant; star, ClinVar star status. *TTN* c.1558dupA does not appear in ClinVar, so the star status and clinical significance are given for a variant causing the identical amino-acid change. *These variants were not considered actionable by the NHS Clinical Genetics team and were not returned.

category	disease	gene	c.	p.	clin sig	actionable	consequence	LoF	star	
cancer	MYH-associated polyposis	<i>MUTYH</i>	c.452A>G	p.Tyr151Cys	P/LP	P and LP (2 var)	missense	0	2	
		<i>MUTYH</i>	c.1103G>A	p.Gly368Asp	P/LP	P and LP (2 var)	missense	0	2	
		<i>MUTYH</i>	c.1130C>T	p.Pro377Leu	pathogenic	P and LP (2 var)	missense	0	2	
metabolic	Wilson disease	<i>ATP7B</i>	c.122A>G	p.Asn41Ser	P/LP	P and LP (2 var)	missense	0	2	
		<i>ATP7B</i>	c.1745_1746del	p.Ile582fs	P/LP	P and LP (2 var)	frameshift	1	2	
		<i>ATP7B</i>	c.1772G>A	p.Gly591Asp	P/LP	P and LP (2 var)	missense	0	2	
		<i>ATP7B</i>	c.2605G>A	p.Gly869Arg	P/LP	P and LP (2 var)	missense	0	2	
		<i>ATP7B</i>	c.2662A>C	p.Thr888Pro	P/LP	P and LP (2 var)	missense	0	2	
		<i>ATP7B</i>	c.2930C>T	p.Thr977Met	pathogenic	P and LP (2 var)	missense	0	2	
		<i>ATP7B</i>	c.3007G>A	p.Ala1003Thr	P/LP	P and LP (2 var)	missense	0	2	
		<i>ATP7B</i>	c.3083_3085delinsG	p.Lys1028fs	pathogenic	P and LP (2 var)	frameshift	1	2	
	biotinidase deficiency	<i>BTD</i>	c.1308A>C	p.Gln436His	P/LP	P and LP (2 var)	missense	0	2	
		<i>BTD</i>	c.1552C>T	p.Arg518Cys	pathogenic	P and LP (2 var)	missense	0	2	
	hereditary haemochromatosis	<i>HFE</i>	c.845G>A	p.Cys282Tyr	pathogenic	C282Y homs only	missense	0	2	
	Pompe disease	<i>GAA</i>	c.841C>T	p.Arg281Trp		LP	P and LP (2 var)	missense	0	3
		<i>GAA</i>	c.1194+3G>C		.	LP	P and LP (2 var)	splice region	0	3
		<i>GAA</i>	c.1210G>A	p.Asp404Asn		pathogenic	P and LP (2 var)	missense	0	3
<i>GAA</i>		c.2238G>C	p.Trp746Cys		pathogenic	P and LP (2 var)	missense	0	3	

Table 2 Summary of non-singleton autosomal recessive actionable variants in the cohort of 4,198 participants. The diseases are grouped into the categories of cancer and metabolic. c., coding sequence change; p., protein sequence change; clin sig, clinical significance according to ClinVar; LP, likely pathogenic; P/LP, pathogenic/likely

pathogenic; actionable, variant categories considered to be actionable; LOF, loss of function; consequence, the molecular consequence of the variant; star, ClinVar star status; 2 var, 2 variants must be present, so either homozygous or compound heterozygous for the P/LP variant; homs only indicates that only homozygotes for the named variant should be reported.

Gene 1	variant ID	inheritance	genotype	Gene 2	variant ID	inheritance	genotype
<i>BRCA1</i>	c.5207T>C	AD	het	<i>PMS2</i>	c.137G>T	AD	het
<i>BRCA2</i>	c.6275_6276del	AD	het	<i>MSH6</i>	c.742C>T	AD	het
<i>BRCA2</i>	c.517-2A>G	AD	het	<i>GAA</i>	c.841C>T	AR	hom
<i>BRCA2</i>	c.5073dupA	AD	het	<i>HFE</i>	c.845G>A	AR	hom

Table 3. Actionable genotype co-occurrences. AD, autosomal dominant; het, heterozygous; hom, homozygous.

gene	c.	p.	disease	inher	maf.ork	ork/ukb	maf.shet	shet/ukb	group	origin
<i>BRCA1</i>	c.5207T>C	p.Val1736Ala	Hereditary breast ovarian cancer	AD	0.00478	470	0	0	Orkney	Westray
<i>BRCA2</i>	c.517-2A>G	.		AD	0	0	0.00237	155	Shetland	Whalsay
<i>ATP7B</i>	c.3083_3085delinsG	p.Lys1028fs	Wilson disease	AR	0	0	0.00475	180	Shetland	Burra
<i>ATP7B</i>	c.3007G>A	p.Ala1003Thr		AR	0	0	0.00356	350	Shetland	Sandsting/Lunnasting/Delting
<i>ATP7B</i>	c.1772G>A	p.Gly591Asp		AR	0.00215	66	0	0	Orkney	Westray
<i>TTN</i>	c.93396_93400del	p.Ala31133_Trp31134insTer	Dilated cardiomyopathy	AD	0	0	0.00380	3700	Shetland	Yell
<i>TTN</i>	c.67519C>T	p.Gln22507Ter		AD	0.00048	700	0.00071	470	Orkney	West Mainland
<i>KCNH2</i>	c.1750G>A	p.Gly584Ser	Long QT syndrome	AD	0	0	0.00119	90	Shetland	Aithsting, Unst
<i>MUTYH</i>	c.1205C>T	p.Pro377Leu	<i>MYH</i> -associated polyposis	AR	0.00431	70	0.00047	8	Orkney	Westray
<i>GAA</i>	c.1210G>A	p.Asp404Asn	Pompe disease	AR	0.00287	74	0	0	Orkney	St. Andrews

Table 4 Founder effects on ten actionable variants in Orkney and Shetland. Drifted variants were defined as actionable variants with an increase in frequency over 50-fold higher than UKB, a pedigree origin before c.1800 CE and a minor allele count of ≥ 5 . For UKB, we used the allele frequency browser (based on ~490k WGS). c., complementary DNA position and nucleotide change; p., protein position and amino-acid change; inher, inheritance; maf.ork, minor allele frequency in Orkney; ork/ukb, fold uplift in frequency in Orkney over UKB; maf.shet, minor allele frequency in Shetland; shet/ukb, fold uplift in frequency in Shetland over UKB; group, island group the variant has drifted upwards in; origin, subpopulation (parish, isle or region) where the variant arose (by tracing back pedigrees) or has become particularly common.

Actionable genotype carriers	Category
64	Results letters sent, including one to Next of Kin
33	Not consented - did not reply to Return of Results consent invitation
8	Deceased and no request from Next of Kin
2	Answered no to Return of Results consent invitation
10	Not deemed returnable by NHS
117	TOTAL ACTIONABLE GENOTYPE CARRIERS, including <i>BRCA1</i> males and accounting for co-occurrences

Table 5 Summary of carriers of actionable genotypes and results returned. Consent was only sought 8-18 years after recruitment, which is probably why 28% of actionable genotype carriers did not reply to the invitation. A further 11% were deceased, while 2.7% replied choosing not to have return of results. NHS, National Health Service.